Skip to main content

Table 3 Multivariable logistic regression results for prevalence of maternal adverse effectsa

From: Inappropriate use of ritodrine hydrochloride for threatened preterm birth in Japan: a retrospective cohort study using a national inpatient database

 

Odds ratio

95% CI

P value

Age (years)

  ≥ 40

2.07

1.60

to

2.67

< 0.001

 35–39

1.66

1.34

to

2.07

< 0.001

 30–34

1.45

1.17

to

1.79

< 0.001

 25–29

1.20

0.96

to

1.50

0.12

  < 20

0.76

0.45

to

1.27

0.29

 20–24 (reference)

1.00

 

to

  

BMI (kg/m2)

  

to

  

  ≥ 30.00

2.29

1.89

to

2.76

< 0.001

 25.0–29.9

1.43

1.27

to

1.61

< 0.001

  < 18.5

0.85

0.67

to

1.08

0.18

 18.5–24.9 (reference)

1.00

    

Smoking

 Yes

1.10

0.94

to

1.28

0.23

 No

1.00

    

Multiple births

 Yes

1.08

0.94

to

1.25

0.28

 No

1.00

    

PROM

 Yes

0.74

0.51

to

1.06

0.10

 No

1.00

    

Placenta praevia

 Yes

1.23

1.03

to

1.46

0.02

 No

1.00

    

Gestational age at admission

0.91

0.90

to

0.92

< 0.001

Duration of ritodrine hydrochloride

  ≤ 48 h (reference)

1.00

    

 3–6 days

1.45

1.13

to

1.87

< 0.001

 7–13 days

1.90

1.49

to

2.42

< 0.001

 14–27 days

2.56

2.05

to

3.19

< 0.001

  ≥ 28 days

4.17

3.39

to

5.14

< 0.001

  1. BMI body mass index, PROM premature rupture of membranes at admission, CI confidence interval
  2. aComposite outcome including any of the following: lung edema, granulocytopenia, rhabdomyolysis, thromboembolism, and gestational diabetes mellitus
Back to article page

BMC Pregnancy and Childbirth

ISSN: 1471-2393

Contact us